LEXINGTON, Mass., Nov. 19, 2020 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, will demonstrate the FDR D-EVO III, an industry-first, glass-free digital radiography (DR) detector with Irradiated Side Sampling (ISS) technology, and the latest additions to Fujifilm's Clinica family digital x-ray suites - FDR Clinica X OTC and FDR Clinica FS – during the 2020 Radiological Society of North America (RSNA) annual meeting.
Previewed for the first time at RSNA 2019, the FDR D-EVO III DR detector is now available in 14x17 and 17x17 sizes across the United States. Engineered to improve detective quantum efficiency (DQE) for clearer images at lower doses, the FDR D-EVO III is currently the lightest 14x17 detector on the market with patented ISS. The groundbreaking detector could be paired with Fujifilm's advanced image processing options, such as Virtual Grid and Dynamic Visualization II.
"Fujifilm is continuing its commitment to deliver innovative solutions by working with customers to learn how we can provide technology solutions that address their needs," said Robert Fabrizio, director of strategic marketing, modality solutions, FUJIFILM Medical Systems U.S.A., Inc. "The leap-forward design of FDR D-EVO III provides imaging departments with a smart solution to endure tough medical environments and minimize life cycle costs. Imaging departments will be able to invest in a smart solution, while providing leading-edge technology to their patients that is built to last well into the future."
In addition to the FDR D-EVO III and Fujifilm's line of DR detectors and mobile DR solutions, Fujifilm will spotlight its newest digital X-ray suites during the virtual RSNA show, including:
"Today's hospitals and healthcare facilities are challenged to deliver rapid imaging exams combined with heightened productivity demands, making it essential that their X-ray systems are able to perform seamlessly," said Rick Banner, Senior Director of Marketing, Modality Solutions, FUJIFILM Medical Systems U.S.A., Inc. "Fujifilm's digital suites with advanced features meet that need without compromising image quality and precision."
The FDR Clinica X OTC Suite is not commercially available in the U.S.
Fujifilm's U.S. patented ISS technology is used in its FDR D-EVO and FDR ES detectors.
To learn more information, or book your virtual RSNA demo with Fujifilm, visit https://www.infowebpage.com/FujiRSNA2020/
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It's ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm's in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit www.fujifilmhealthcare.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $22.1 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
SOURCE FUJIFILM Medical Systems U.S.A., Inc.